Clinical trials: Disease-Free Survival
Congestive Heart Failure
Vitamin D and Mortality in Heart Failure
Despite significant therapeutic improvements, congestive heart failure (CHF) patients still have a poor prognosis. Currently, 5-year survival rates are only 35-50%.
- Trial name
- EVITA (NCT01326650)
- Testing
- Vitamin D
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- Heart and Diabetes Center North-Rhine Westfalia
Cervical Cancer, Postoperative Pain
Laparoscopic vs Abdominal Radical Hysterectomy In Patients With Early Cervical Cancer
The purpose of this study is to determine whether laparoscopic radical hysterectomy for early cervical cancer will has decreased postoperative pain intensity compared to abdominal radical hysterectomy with similar postoperative…
- Trial name
- NCT01258413
- Testing
- Laparoscopic Radical Hysterectomy + pelvic lymphadenectomy, Abdominal radical hysterectomy
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Hospital Nossa Senhora da Conceicao
Non-small Cell Lung Cancer
A Study of Avastin (Bevacizumab) in Combination With Docetaxel and Cisplatin in Patients With Metastatic or Locally Advanced Non-small Cell Lung Cancer
This study assessed the efficacy and safety of Avastin in combination with docetaxel and cisplatin as first-line treatment of patients with metastatic or locally advanced non-small cell lung cancer.
- Trial name
- NCT00661778
- Testing
- Bevacizumab, Cisplatin, Docetaxel
- Where
- 14 sites in Spain
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Melanoma
CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma
The purpose of this study is to see whether the combination of low-dose Cyclophosphamide and Anti-CTLA4 (Ipilimumab) will stop tumor growth in patients with advanced skin cancer.
- Trial name
- NCT01740401
- Testing
- Cyclophosphamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Advanced Malignancy, Advanced Solid Cancers
ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers
The purpose of this first-in-human study is to explore the safety, pharmacokinetics and effects of the study drug ADCX-020 in patients with advanced and metastatic solid tumors.
- Conditions
- Advanced Malignancy, Advanced Solid Cancers, Metastatic Solid Tumors
- Trial name
- NCT07238075
- Testing
- ADCX-020
- Where
- 9 sites in Australia, Spain
- Volunteers
- 290 people
- Sponsor
- Adcytherix SAS
Disease-free Survival, Overall Survival
Jejunoileal vs Gastric GIST in the Era of Imatinib.
Introduction: Gastrointestinal Stromal Tumors (GISTs) located in the jejunum or ileum (JI-GIST) are considered of worse prognosis compared to other locations. It has been suggested that this dogma should be revised.
- Conditions
- Disease-free Survival, Overall Survival, Recurrence
- Trial name
- NCT03923400
- Where
- Spain
- Volunteers
- 77 people
- Sponsor
- Hospital Universitario Virgen de la Arrixaca
Foreign Body Granuloma, Surgery
"Outcomes of Surgical Removal of Foreign Body Granulomas"
Illicit subcutaneous injection of high-viscosity fluids for restoration and improvement of body contour is a growing trend all around the world. Many local and systemic complications have been described.
- Conditions
- Foreign Body Granuloma, Surgery, Complication
- Trial name
- NCT04661969
- Testing
- Surgery
- Where
- Mexico
- Volunteers
- 35 people
- Sponsor
- Hospital Angeles del Pedregal
Prostate Cancer
Long-term Better Than Short-term ADT With Salvage RT
A randomized, multicenter, prospective PHASE II trial to assess the effect of short- versus long-term adjuvant ADT with high dose salvage radiotherapy on distant metastasis free survival in case of biochemical relapse (BR) after…
- Trial name
- LOBSTER (NCT04242017)
- Testing
- Triptoreline
- Where
- 3 sites in Belgium
- Volunteers
- 394 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Metastatic Renal Cell Carcinoma
Pretreatment 18F-FDG PET/CT Radiomics for Predicting Response to First-Line Targeted Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma
This single-center retrospective observational study evaluates whether quantitative imaging features from pretreatment 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) can help predict…
- Trial name
- NCT07827482
- Testing
- Pretreatment 18F-FDG PET/CT, Axitinib Plus Pembrolizumab or Toripalimab
- Where
- China
- Volunteers
- 228 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Cancer
Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer
Cancer is the second leading cause of death in the United States, with approximately 90% of deaths resulting from patients with metastatic spread.
- Trial name
- NCT00463060
- Testing
- sunitinib malate (Sutent), radiotherapy
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Lymphoma, Large B-Cell, Diffuse
R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma
The combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP regimen) has been the first-line chemotherapy for elderly patients with diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT02428751
- Testing
- Pegylated liposomal doxorubicin, Doxorubicin, Rituximab
- Where
- 7 sites in China
- Volunteers
- 216 people
- Sponsor
- Wenqi Jiang
Immune Checkpoint Inhibitors, Anti-programmed Death-1 Antibody
PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer
This study is to investigate retrospectively the effects of combination of immune checkpoint inhibitors anti-programmed death-1 antibody (PD-1 antibody) and radiotherapy for recurrent, metastatic and persistent advanced cervical…
- Conditions
- Immune Checkpoint Inhibitors, Anti-programmed Death-1 Antibody, Radiotherapy, Recurrent Cervical Carcinoma
- Trial name
- NCT05310305
- Testing
- Radiotherapy for targeted lesions and PD-1 antibody
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Lei Li
Renal Cell Carcinoma, Neoadjuvant
Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
The study included 298 RCC patients who were at high risk for recurrence after nephrectomy (T2G3-4 or T3-4 or N1). They were randomly divided to receive axitinib plus PD-1 + surgery or surgery alone at a ratio of 1:1, so as to…
- Trial name
- NCT05738694
- Testing
- Axitinib plus Toripalimab, nephrectomy
- Where
- 8 sites in China
- Volunteers
- 298 people
- Sponsor
- ZHOU FANGJIAN
Myelofibrosis, Primary Myelofibrosis (PMF)
Peri-Transplant Gecacitinib in Patients With Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
This study aims to evaluate the efficacy, safety, and feasibility of peri-transplant gecacitinib in patients with myelofibrosis undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Conditions
- Myelofibrosis, Primary Myelofibrosis (PMF), Secondary Myelofibrosis
- Trial name
- NCT07904871
- Testing
- Peri-Transplant Gecacitinib
- Volunteers
- 46 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
This study will evaluate the efficacy and safety of brief induction therapy with a chemotherapeutic regimen containing MabThera, followed by either maintenance therapy with MabThera or no further therapy.
- Trial name
- NCT01144364
- Testing
- rituximab [Mabthera/Rituxan]
- Where
- 45 sites in Italy
- Volunteers
- 234 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
A Randomized Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer
The purpose of this study is to determine whether Paclitaxel and bevacizumab showed improved PFS compared to paclitaxel alone. Recent results of the AVADO study report a similar result for the combination of docetaxel and…
- Trial name
- TABEA (NCT01200212)
- Testing
- Taxane, Avastin, Taxane, Avastin, Xeloda
- Where
- Germany
- Volunteers
- 432 people
- Sponsor
- GBG Forschungs GmbH
Wound; Head, Multiple, Wound; Head, Scalp
Short Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
This study will evaluate the use of free autologous dermal fat grafting (also called free dermal fat autografting) to treat complex craniofacial wounds that have failed standard treatment and to understand how well these grafts…
- Conditions
- Wound; Head, Multiple, Wound; Head, Scalp, Wound; Head, Wound Infection
- Trial name
- FTFDT3 (NCT03872544)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dufresne, Craig, MD, PC
Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancers
Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer
This is a prospective, single-center, single-arm exploratory clinical study designed to evaluate the efficacy and safety of liposomal irinotecan combined with enlonstobart in patients with platinum-resistant recurrent ovarian…
- Conditions
- Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancers, Epithelial Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT07591831
- Testing
- Liposomal Irinotecan
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
High-Risk Cancer, Urothelial Carcinoma Bladder
Adjuvant Radiotherapy Versus Observation After Radical Cystectomy in High Risk Urothelial Bladder Cancer
This is a prospective randomized clinical trial in high risk urothelial bladder cancer to compare adjuvant radiotherapy versus observation after radical cyctectomy.
- Trial name
- NCT04740866
- Testing
- Adjuvant Radiotherapy
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Cairo University
Breast Cancer, HER2-positive Breast Cancer
Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
At present, the incidence rate of breast cancer has exceeded that of lung cancer, becoming the largest cancer in the world. HER2 overexpression breast cancer accounts for about 20%~30% of all breast cancer patients.
- Trial name
- NCT05918328
- Testing
- Albumin paclitaxel+trastuzumab+pyrrolitinib, Docetaxel+Carboplatin+trastuzumab+Parstuzumab
- Where
- China
- Volunteers
- 610 people
- Sponsor
- Henan Cancer Hospital